The U.S. government, the European Union, and the governments of Japan and Australia have all enacted legislation to encourage pharmaceutical companies to develop drugs for diseases that have a small market. The Orphan Drug Act, passed in the United States in 1983, allows companies that develop drugs for disorders affecting fewer than 200,000 Americans to sell them without competition for seven years, and also allows them to get clinical trial tax incentives. The European Union has enacted similar legislation, Regulation (EC) No 141/2000. 1 Under the ODA and EU legislation, many orphan drugs have been developed, including drugs to treat glioma, multiple myeloma, cystic fibrosis, phenylketonuria, snake venom poisoning, and idiopathic thrombocytopenic purpura. In the USA, from January 1983 to June 2004, a total of 1,129 different orphan drug designations have been granted by the Office of Orphan Products Development (OOPD) and 249 orphan drugs have received marketing authorization. In contrast, the decade prior to 1983 saw fewer than ten such products come to market. This paper will investigate the impact of the introduction of new orphan drugs on premature mortality from rare diseases using longitudinal, disease-level data obtained from a number of major databases. The analysis will be performed using data from two countries: the U.S. (using annual data during the period [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] and France (using annual data during the period [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] .
In the next section, we describe the econometric model we will estimate. Data sources and descriptive statistics are discussed in Section II. Empirical results are presented in Section III. The final section contains a summary and conclusions.
I. Econometric model
To investigate the impact of the introduction of new orphan drugs on premature mortality from rare diseases, we will estimate models of the following form: ln(MORT it ) =  ln (DRUG_STOCK i,t-k 
(1) (i = 1,…, I; t = 1999,…,2007) 1 The EU's definition of an orphan condition is broader than that of the USA, in that it also covers some tropical diseases that are primarily found in developing nations. aggregate production function such that an economy's output depends on the "stock of ideas" that have previously been developed, as well as on the economy's endowments of labor and capital. Eq. (1) may be considered a health production function, in which the mortality rate is an (inverse) indicator of health output or outcomes, and the cumulative number of drugs approved (DRUG_STOCK) is analogous to the stock of ideas.
Since the model includes disease and year fixed effects, it is a difference-indifferences model. Negative and significant estimates of  would indicate that, ceteris paribus, diseases with above-average increases in the lagged cumulative number of drugs approved had above-average declines in premature mortality. All models will be estimated via weighted least-squares, using appropriate weights. Clustered (within disease) standard errors will be reported.
We will analyze two measures of premature mortality: the number of potential years of life lost before ages 65 and 75:
PYLL65 it =  a max(65 -a, 0) N_DEATH ait PYLL75 it =  a max(75 -a, 0) N_DEATH ait 2 Romer, Paul (1990) , "Endogenous technical change," Journal of Political Economy 98, S71-S102.
where N_DEATH ait is the number of deaths at age a from disease i in year t.
It would be ideal to control for changes in disease incidence or prevalence. For example, we would prefer to estimate the following model:
or this more general model:
where PREV it = the prevalence of (number of people at risk to die from) disease i at the beginning of year t. If the growth in the stock of drugs were correlated across diseases with the growth in prevalence, failure to control for prevalence would cause estimates of  in eq.
(1) to be biased. On theoretical grounds, one might expect the correlation across diseases between the growth in the stock of drugs and the growth in prevalence to be positive, e. g. because pharmaceutical companies are likely to develop more drugs for diseases with the largest (exogenous) increases in prevalence. If this is the case, failure to control for prevalence would cause estimates of  to be biased towards zero: the effect of pharmaceutical innovation on mortality would be underestimated.
Orphanet publishes some data on the prevalence of rare diseases, 3 but the data they publish are cross-sectional, rather than longitudinal. Longitudinal, disease-level U.S. data on incidence (the number of newly diagnosed cases) are available for a subset of orphan diseases: different types of cancer. These data are produced by the Similarly, the ICD10 code assigned by Orphanet to the disease "Colon cancer, Since there is not a distinct ICD10 code for every rare disease, in some cases the ICD10 codes assigned by Orphanet include a broader set of diseases, some of which are not rare. In these cases, the list of drugs contained in the Orphanet database is likely to be quite incomplete, and estimates of DRUG_STOCK would be subject to substantial measurement error. We will attempt to deal with this problem by restricting the sample to diseases with ICD10 codes that are unlikely to include non-rare diseases. In particular,
we will exclude diseases that Orphanet has assigned ICD10 codes for which the average annual number of deaths is "large." Clearly, we should exclude "Lung cancer, small cell," because the average annual number of deaths from the ICD10 code assigned to this disease by Orphanet (C34.9) during the period 1999-2006 was 155,838. The question is, how large is too large to warrant inclusion in the sample?
In the U.S., a disease is considered rare if it afflicts fewer than 200,000 (about 1 in 1500) Americans. The crude mortality rate in the U.S. during the period 1999-2006 was 837.3 deaths per 100,000 population. Therefore, if the mortality rate of people with rare diseases were the same as the mortality rate of the general population, then a disease might be considered rare if it caused less than 1675 (= 2 * 837.3) deaths per year.
However, this is surely too low a threshold, because people with rare diseases are subject to higher mortality rates than other people. Lichtenberg and Waldfogel (2009) demonstrated that the less prevalent a disease, the lower is mean age at death from that disease.
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Further evidence is shown in Conditional mortality rate (number of deaths/prevalence) Total prevalence 11 rare cancers (prev < 200K) 11.6% 1,031,710 13 common cancers (prev > 200K) 3.7% 10,162,919
We will estimate eq. (1) using three different threshold values of the maximum average annual number of deaths in each country (the U.S. and France). In the U.S., the three threshold values are 3200, 4800, and 6400 deaths per year. These are the maximum number of deaths from diseases with lower than 1/1500 prevalence that would occur if mortality rates from these diseases were about 2 times, 3 times, and 4 times, respectively, the average mortality rate of Americans. In France, the three threshold values are 600, 
III. Empirical results
Estimates of the effect of the cumulative number of drugs approved on premature mortality from rare diseases are shown in Table 4 . Each estimate in the table comes from a separate model. Each model includes fixed disease effects and fixed year effects. We estimated 72 (=2 * 2 * 3 * 6) models: one for each country (U.S. or France), premature mortality measure (PYLL65 or PYLL75), maximum average annual number of deaths value (3200, 4800, and 6400 for the U.S.; 600, 900, and 1200 for France), and DRUG_STOCK lag (0-5 years). Each model was estimated via weighted least squares, where the weight was the mean of the disease's premature mortality measure during the entire sample period, e. g.
Estimates for the U. S., 1999-2006 . In the first set of estimates (Set 1), we estimate the model using U.S. data, the premature mortality measure is the number of potential years of life lost before age 65, and the maximum average annual number of deaths is 3200.
The coefficient on the contemporaneous drug stock is not statistically significant, which is not surprising, since most patients probably don't have access to a drug during the year 9 In this calculation, if the same drug is used for N diseases, it is counted N times.
in which it is approved by the FDA.
10
However the coefficients on the DRUG_STOCK 1, 3, and 4 years earlier are negative and highly significant (although the coefficient on the DRUG_STOCK 2 years earlier is not). This signifies that premature mortality from a rare disease tends to decline 3 to 4 years after new drugs to treat the disease have been approved. The elasticity of premature mortality with respect to the cumulative stock of drugs 3-4 years earlier is about -.85.
The next two sets of estimates (Sets 2 and 3) show that increasing the maximum average annual number of deaths value from 3200 to either 4800 or 6400 has very little effect on the estimates. The next three sets of estimates (Sets 4, 5, and 6) show that changing the premature mortality measure from the number of potential years of life lost before age 65 to the number of potential years of life lost before age 75 also has very little effect on the estimates.
Estimates for France, 2000 France, -2007 . The remaining sets of estimates (Sets 7-12) examine the effect of the cumulative number of drugs approved on premature mortality from rare diseases in France. In Set 7, the premature mortality measure is the number of potential years of life lost before age 65, and the maximum average annual number of deaths is 600. The estimates indicate that premature mortality is not related to the DRUG_STOCK 0, 1, and 2 years earlier, but it is significantly inversely related to the DRUG_STOCK 3-5 years earlier. The next two sets of estimates (Sets 8 and 9) show that increasing the maximum average annual number of deaths value from 600 to either 900 or 1200 has very little effect on the estimates. The last three sets of estimates (Sets 10, 11, and 12) show that changing the premature mortality measure from the number of potential years of life lost before age 65 to the number of potential years of life lost before age 75 also has very little effect on the estimates.
10 Some patients may have access to drugs prior to marketing approval. According to Liu and Davis, "there are occasions when a clinical trial has ended and subjects are allowed to continue taking the investigational drug, benefiting from its use while the sponsor pursues marketing approval. This may be referred to as compassionate use of an investigational drug. Compassionate use of a drug may also be granted by the FDA when a drug that has been marketed or is under investigation in another country (but is not available in the U. and the DRUG_STOCK lag is set to 3 years, since the estimates in Table 4 indicate that this lag provides the best fit to the data.  cond in eq.may be interpreted as the average annual growth rate of premature mortality, holding constant (or conditional on) the lagged stock of drugs, i.e. in the absence of new drug approvals. The drug stock variable is excluded from eq. (3), so  uncond may be interpreted as the actual (unconditional) growth rate of premature mortality. ( uncond  cond may be interpreted as the reduction in the growth rate of premature mortality attributable to lagged new drug approvals.
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These calculations are shown for the broadest definitions of rare diseases we have considered (max(mean_deaths) equal to 6400 in the U.S. and 1200 in France) in the following Line 2 shows that the reduction in the growth rate of potential years of life lost to rare diseases before age 75 attributable to lagged new drug approvals is almost identical:
4.1%. In this case, the estimates imply that, in the absence of new drug approvals, potential years of life lost before age 75 would have increased faster than the population age 0-74, but this difference is not statistically significant.
Line 3 shows that, in France, PYLL65 declined at an average annual rate of 1.8%.
The estimates imply that, in the absence of lagged new drug approvals, it would have declined at a rate of 0.6%. The estimated reduction in the growth rate of PYLL65 attributable to lagged new drug approvals in France (1.1%) is about one-fourth the estimated reduction in the U.S. This is not surprising, since the magnitudes of the U.S.
estimates of  are about four times as large as the magnitudes of the French estimates.
Line 4 shows that, in France, PYLL75 declined at an average annual rate of 1.3%, and that the estimates imply that, in the absence of lagged new drug approvals, it would have declined at a rate of 0.5%.
IV. Summary and conclusions
This paper has investigated the impact of the introduction of new orphan drugs on premature mortality from rare diseases using longitudinal, disease-level data obtained from a number of major databases. The analysis was performed using data from two countries: the U.S. (during the period [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] and France (during the period [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] . For both countries, we estimated models using two alternative definitions of premature mortality, several alternative criteria for inclusion in the set of rare diseases,
and several values of the potential lag between new drug approvals and premature mortality reduction.
Both the U.S. and French estimates indicate that, overall, premature mortality from rare diseases is unrelated to the cumulative number of drugs approved 0-2 years earlier, but is significantly inversely related to the cumulative number of drugs approved 3-4 years earlier. This delay is not surprising, since most patients probably don't have access to a drug until several years after it has been launched. Although the estimates for the two countries are qualitatively similar, the estimated magnitudes of the U.S.
coefficients are about four times as large as the magnitudes of the French coefficients.
This may be partly due to greater errors in measuring dates of drug introduction in France.
Our estimates indicate that, in the U.S., potential years of life lost to rare diseases before age 65 declined at an average annual rate of 3.3%, and that, in the absence of lagged new drug approvals, PYLL65 would have increased at a rate of 0.9%. Since the U.S. population age 0-64 was increasing at the rate of 1.0% per year, this means that Table 4 Estimates of the effect of the cumulative number of drugs approved on premature mortality from rare diseases 
